Email your news and story ideas to: [email protected]
Pharma giant pays out $24.9m in whistleblower case
Californian biopharmaceutical company Amgen has agreed to pay $24.9 million to resolve claims that it paid sweeteners to pharmacies so that elderly patients in nursing homes would be switched to Amgen drugs.
Sign up for our free daily newsletter
YOUR PRIVACY - PLEASE READ CAREFULLY DATA PROTECTION STATEMENT
Below we explain how we will communicate with you. We set out how we use your data in our Privacy Policy.
Global City Media, and its associated brands will use the lawful basis of legitimate interests to use
the
contact details you have supplied to contact you regarding our publications, events, training,
reader
research, and other relevant information. We will always give you the option to opt out of our
marketing.
By clicking submit, you confirm that you understand and accept the Terms & Conditions and Privacy Policy
Delaware law firm Grant & Eisenhofer represented whistleblower Frank Kurnik - a long-time Amgen employee.
Pharmaceutical safety
Reuben Guttman, a Grant & Eisenhofer partner who heads the firm’s whistleblower practice, said that yesterday’s settlement agreement sets an important precedent to the medical community. ‘The conduct alleged in this case is yet another example of the pharmaceutical industry placing marketing goals over patient needs,’ he said.
Mr Guttman continued: ‘The alleged conduct affected some of the most vulnerable of our citizens – the elderly in nursing homes. For situations like this, there has to be a pharmaceutical safety and investigation board to make an even broader report to the public so that this never happens again. We hope this settlement is an impetus for Congress to act.’
